Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype

Montes‐Moreno, Santiago; Gonzalez-Medina, Ana-Rosa; Rodríguez-Pinilla, Socorro-María; Maestre, Lorena; Sánchez-Verde, Lydia; Roncador, Giovanna; Mollejo, Manuela; Garcı́a, Juan F.; Menárguez, Javier; Montalbán, Carlos; Ruiz-Marcellan, MC; Conde, Eulogio; Piris, Miguel Á.

doi:10.3324/haematol.2009.016113

Cited by 125 publications

(118 citation statements)

References 31 publications

Supporting

Mentioning

111

Contrasting

Order By: Relevance

“…13 BLIMP1 and XBP1 are expressed in plasma cell neoplasias and aggressive lymphomas with plasmablastic differentiation but their distribution in small B-cell lymphomas has been less investigated. 43 We found a relatively high expression of these transcriptions factors in mantle cell lymphoma and both of them were significantly more common in SOX11-negative than in -positive tumors. The knockdown of SOX11 by shRNA in mantle cell lymphoma cell lines leads to a downregulation of PAX5 and a switch toward the terminal B-cell differentiation program with increased expression of BLIMP1 and XBP1.…”

Section: Discussionmentioning

confidence: 67%

Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype

et al. 2015

View full text Add to dashboard Cite

Mantle cell lymphoma is a mature lymphoid neoplasm characterized by the t(11;14)(q13;q32) and cyclin D1 overexpression. SOX11 is a transcription factor commonly overexpressed in these tumors but absent in most other mature B-cell lymphomas whose function is not well understood. Experimental studies have shown that silencing of SOX11 in mantle cell lymphoma cells promotes the shift from a mature B cell into an early plasmacytic differentiation phenotype, suggesting that SOX11 may contribute to tumor development by blocking the B-cell differentiation program. The relationship between SOX11 expression and terminal B-cell differentiation in primary mantle cell lymphoma and its relationship to the plasmacytic differentiation observed in occasional cases is not known. In this study we have investigated the terminal B-cell differentiation phenotype in 60 mantle cell lymphomas, 41 SOX11-positive and 19 SOX11-negative. Monotypic plasma cells and lymphoid cells with plasmacytic differentiation expressing cyclin D1 were observed in 7 (37%) SOX11-negative but in none of 41 SOX11-positive mantle cell lymphomas (Po0.001). Intense cytoplasmic expression of a restricted immunoglobulin light chain was significantly more frequent in SOX11-negative than -positive tumors (58 vs 13%) (P = 0.001). Similarly, BLIMP1 and XBP1 expression was also significantly more frequent in SOX11-negative than in -positive cases (83 vs 34% and 75 vs 11%, respectively) (P = 0.001). However, no differences in the expression of IRF4/MUM1 were observed among these subtypes of mantle cell lymphoma. In conclusion, these results indicate that SOX11-negative mantle cell lymphoma may be a particular subtype of this tumor characterized by more frequent morphological and immunophenotypic terminal B-cell differentiation features that may be facilitated by the absence of SOX11 transcription factor.

show abstract

Section: Discussionmentioning

confidence: 67%

Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Cytologically, the cells have immunoblastic or sometimes plasmablastic features, but they exhibit a plasmacytic phenotype with the absence of CD20 and PAX5 and expression of CD38, CD138, and BLIMP1 (Figure 1). 52,53 These lymphomas include anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma, plasmablastic lymphoma (PBL), and the human herpesvirus 8-related primary effusion lymphoma and large B-cell lymphoma associated with multicentric Castleman disease. PBL and human herpesvirus 8-related lymphomas usually occur in patients with immunodeficiency, most often HIV, and the tumors cells are infected by EBV, but usually with a latency type 1.…”

Section: Diffuse Large B-cell Lymphomasmentioning

confidence: 99%

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

Campo

Swerdlow

Harris

et al. 2011

Blood

1,758

1,414

View full text Add to dashboard Cite

The World Health Organization classification of lymphoid neoplasms updated in 2008 represents a worldwide consensus on the diagnosis of these tumors and is based on the recognition of distinct diseases, using a multidisciplinary approach. The updated classification refined the definitions of well-recognized diseases, identified new entities and variants, and incorporated emerging concepts in the understanding of lymphoid neoplasms. However, some questions were unresolved, such as the extent to which specific genetic or molecular alterations define certain tumors, and the status of provisional entities, categories for which the World Health Organization working groups felt there was insufficient evidence to recognize as distinct diseases at this time. In addition, since its publication, new findings and ideas have been generated. This review summarizes the scientific rationale for the classification, emphasizing changes that have had an effect on practice guidelines. The authors address the criteria and significance of early or precursor lesions and the identification of certain lymphoid neoplasms largely associated with particular age groups, such as children and the elderly. The issue of borderline categories having overlapping features with large B-cell lymphomas, as well as several provisional entities, is reviewed. These new observations chart a course for future research in the field. (Blood. 2011

show abstract

“…In that study, EBER+/CD30+ DLBCL patients had worse outcome than that in EBER+/CD30-DLBCL patients. Montes-Moreno et al demonstrated that the acquisition of a partial plasmablastic phenotype in DLBCL is associated with aggressive clinical behavior (13). Several groups showed that addition of the anti-CD20 monoclonal antibody, rituximab, to anthracycline-based chemotherapy has clearly improved survival outcomes in patients with DLBCL in different clinical settings (14).…”

Section: Discussionmentioning

confidence: 99%

Primary Gastric EBV-positive Diffuse Large B Cell Lymphoma (DLBCL) of the Elderly with Plasmablastic Differentiation

Treviño

Yang

et al. 2018

View full text Add to dashboard Cite

Abstract. Epstein-Barr virus (EBV)-positive diffuse large B cell lymphoma (DLBCL) of the elderly is a rare subtype of B-cell neoplasms. Primary gastric EBV-positiveEBV-positive DLBCL of the elderly is characterized by higher age distribution and an aggressive clinical course with a median survival of 2 years in Asian patients. The sites of primary extranodal involvement include the skin, soft tissue, bones, nasal cavity, pharynx/hypopharynx, tonsils, tongue, lung, pleura, stomach, liver, spleen, peritoneum, cecum, and bone marrow. The neoplastic cells are of B-cell lineage, they express the pan B-cell antigens CD20 and PAX5. Plasmacytoid (or plasmablastic) cases can be CD20 weakly positive or negative, usually has an activated B-cell (ABC) immunophenotype being MUM1 positive and CD10 negative and usually BCL-6 negative. BCL-2 and CD30 are usually positive, while CD15 is negative. Ki-67 generally shows a high proliferation index. Immunoglobulin light chain restriction may be difficult to demonstrate by conventional flow cytometric analysis due to lack of surface expression of immunoglobulin light chains, except in cases with immunoblastic or plasmablastic features in which cytoplasmic immunoglobulin light chain mRNA and protein can be assessed by cytoplasmic flow cytometry or by kappa/Lambda in situ hybridization (ISH). We report a unique primary gastric EBV-positive DLBCL of the elderly with CD138 and MUM1 positive and strong immunoglobulin lambda light chain 413

show abstract

Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype

Cited by 125 publications

References 31 publications

Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype

Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

Primary Gastric EBV-positive Diffuse Large B Cell Lymphoma (DLBCL) of the Elderly with Plasmablastic Differentiation

Contact Info

Product

Resources

About